Company profile OCUL

Ocular Therapeutix Inc
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3... clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib Show More
Quarter analysis & expected interestLast update: February 08 2024 02:03:37.

After 38 days of this quarter the interest is at 49.0. Based on that we can calculate that during remaining 53 days it will total up to 117.0.
Ocular Therapeutix expected interest is significantly lower compared to previous quarter (-75.1%) and same quarter last year (-59.4%).

YearQ1Q2Q3Q4
2019235
577
145.5% QoQ
565
-2.1% QoQ
386
-31.7% QoQ
2020 378
60.9% YoY -2.1% QoQ
427
-26.0% YoY 13.0% QoQ
353
-37.5% YoY -17.3% QoQ
484
25.4% YoY 37.1% QoQ
2021 309
-18.3% YoY -36.2% QoQ
267
-37.5% YoY -13.6% QoQ
257
-27.2% YoY -3.7% QoQ
242
-50.0% YoY -5.8% QoQ
2022 383
23.9% YoY 58.3% QoQ
262
-1.9% YoY -31.6% QoQ
417
62.3% YoY 59.2% QoQ
291
20.2% YoY -30.2% QoQ
2023 288
-24.8% YoY -1.0% QoQ
346
32.1% YoY 20.1% QoQ
172
-58.8% YoY -50.3% QoQ
470
61.5% YoY 173.3% QoQ
2024 49
-83.0% YoY -89.6% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Ocular Therapeutix search interestLast update: February 08 2024 02:03:36.
Correlation coefficient between keyword and revenue is -0.53
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 02:03:38.

The average 5 years interest of Ocular Therapeutix was 27.43 per week.
The last year interest of Ocular Therapeutix compared to the last 5 years has changed by -16.7%.
The interest for Ocular Therapeutix is significantly decreasing.
The last year interest is quite lower compared to 5 years ago. It has decreased by -37.26%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Ocular Therapeutix contact to provide analysis

Correlation between past revenue and Ocular Therapeutix contact search interest

There is not enough data for Ocular Therapeutix contact to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Ocular Therapeutix contact to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Ocular Therapeutix website to provide analysis

Correlation between past revenue and Ocular Therapeutix website search interest

There is not enough data for Ocular Therapeutix website to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Ocular Therapeutix website to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 02:03:42.

After 38 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 53 days it will total up to 0.0.
ReSure Sealant expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
20190
59
inf% QoQ
133
125.4% QoQ
140
5.3% QoQ
2020 22
inf% YoY -84.3% QoQ
85
44.1% YoY 286.4% QoQ
61
-54.1% YoY -28.2% QoQ
85
-39.3% YoY 39.3% QoQ
2021 124
463.6% YoY 45.9% QoQ
124
45.9% YoY 0.0% QoQ
136
123.0% YoY 9.7% QoQ
242
184.7% YoY 77.9% QoQ
2022 70
-43.5% YoY -71.1% QoQ
196
58.1% YoY 180.0% QoQ
93
-31.6% YoY -52.6% QoQ
28
-88.4% YoY -69.9% QoQ
2023 21
-70.0% YoY -25.0% QoQ
172
-12.2% YoY 719.0% QoQ
0
-100.0% YoY -100.0% QoQ
30
7.1% YoY inf% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and ReSure Sealant search interestLast update: February 08 2024 02:03:41.
Correlation coefficient between keyword and revenue is 0.32
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 02:03:44.

The average 5 years interest of ReSure Sealant was 6.98 per week.
The last year interest of ReSure Sealant compared to the last 5 years has changed by -38.54%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -37.0%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 02:03:49.

After 38 days of this quarter the interest is at 55.0. Based on that we can calculate that during remaining 53 days it will total up to 132.0.
DEXTENZA expected interest is significantly lower compared to same quarter last year (-42.6%) but similar to previous quarter.

YearQ1Q2Q3Q4
201940
130
225.0% QoQ
240
84.6% QoQ
214
-10.8% QoQ
2020 55
37.5% YoY -74.3% QoQ
243
86.9% YoY 341.8% QoQ
188
-21.7% YoY -22.6% QoQ
141
-34.1% YoY -25.0% QoQ
2021 158
187.3% YoY 12.1% QoQ
203
-16.5% YoY 28.5% QoQ
190
1.1% YoY -6.4% QoQ
167
18.4% YoY -12.1% QoQ
2022 184
16.5% YoY 10.2% QoQ
173
-14.8% YoY -6.0% QoQ
187
-1.6% YoY 8.1% QoQ
121
-27.5% YoY -35.3% QoQ
2023 230
25.0% YoY 90.1% QoQ
178
2.9% YoY -22.6% QoQ
154
-17.6% YoY -13.5% QoQ
141
16.5% YoY -8.4% QoQ
2024 55
-76.1% YoY -61.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and DEXTENZA search interestLast update: February 08 2024 02:03:49.
Correlation coefficient between keyword and revenue is 0.21
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 02:03:50.

The average 5 years interest of DEXTENZA was 13.0 per week.
The last year interest of DEXTENZA compared to the last 5 years has changed by -6.38%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -1.46%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for OTX-TKI to provide analysis

Correlation between past revenue and OTX-TKI search interest

There is not enough data for OTX-TKI to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for OTX-TKI to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for OTX-TIC to provide analysis

Correlation between past revenue and OTX-TIC search interest

There is not enough data for OTX-TIC to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for OTX-TIC to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for OTX-CSI to provide analysis

Correlation between past revenue and OTX-CSI search interest

There is not enough data for OTX-CSI to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for OTX-CSI to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for OTX-DED to provide analysis

Correlation between past revenue and OTX-DED search interest

There is not enough data for OTX-DED to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for OTX-DED to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for OCUL
Earnings date: 2024-03-07 After close
Company name: Ocular Therapeutix Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-08T20:05:00Z

GlobeNewswire
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-05-06T15:49:28Z

Analyst Upgrades
RBC Capital Reiterates Outperform on Ocular Therapeutix, Maintains $30 Price Target

2026-05-05T11:00:00Z

GlobeNewswire
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

2026-04-29T11:00:00Z

GlobeNewswire
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

2026-04-28T11:00:00Z

GlobeNewswire
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

2026-04-27T11:00:00Z

GlobeNewswire
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences

2026-04-22T11:00:00Z

GlobeNewswire
Ocular Therapeutix™ to Host Investor Day on June 17, 2026

2026-04-14T11:00:00Z

GlobeNewswire
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-04-13T16:59:08Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $21 Price Target

2026-04-13T11:00:00Z

GlobeNewswire
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

2026-04-01T11:00:00Z

GlobeNewswire
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

2026-03-09T20:01:00Z

GlobeNewswire
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-03-03T10:06:48Z

Analyst Upgrades
Clear Street Maintains Buy on Ocular Therapeutix, Raises Price Target to $28

2026-02-24T12:00:00Z

GlobeNewswire
Ocular Therapeutix™ to Participate in March Investor Conferences

2026-02-23T12:00:00Z

GlobeNewswire
Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations